Intelligence Report · ~15 min read
Pulmonary Arterial Hypertension · Prostacyclin Analog Therapeutic Area Assessment
2 signals · 1 insights · 8 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 64%
Evidence
11 items
Sources
3
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Pulmonary Arterial Hypertension · Prostacyclin Analog integrates 2 signals, 1 executive insights, and 8 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 20, 2026
FDA Accepts Supplemental Application for UPTRAVI (Selexipag)
The FDA has accepted a supplemental application for UPTRAVI (selexipag) from Actelion.
View detail - signalJun 6, 2026
FDA Accepts Supplement Application for Tyvaso (Treprostinil)
The FDA has accepted a supplemental application for Tyvaso, an inhaled formulation of treprostinil.
View detail - regulatoryJul 20, 2026
IND Application Reporting: IND Safety Reports
This webpage provides an overview of investigational new drug application (IND) safety reporting requirements for sponsors set forth in 21 CFR 312.32 and additional resources, including FDA guidances, related to these requirements.
View detail - regulatoryJul 20, 2026
Investigational New Drug (IND) Application
Get to know the investigational new drug application (IND). This includes the types, laws and regulations, and emergency use of INDs.
View detail - regulatoryJul 20, 2026
FDA AP — SELEXIPAG (ORIG)
Application ANDA214055. Sponsor: RK PHARMA. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: SELEXIPAG.
View detail - regulatoryJul 20, 2026
FDA AP — BAXFENDY (ORIG)
Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
View detail - insightJun 6, 2026
Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH Market
The FDA's acceptance of the supplemental application for Tyvaso signifies a potential shift in the competitive landscape for pulmonary arterial hypertension treatments. This could enhance United Therapeutics' market position and necessitate strategic adjustments from competitors. Regulatory context from FDA (FDA AP — BAXFENDY (ORIG)) supports the near-term read. Assessment grounded in 6 ranked evidence items (3 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 1 risk-calibrated assessments for portfolio review. 8 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 1 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
IND Application Reporting: IND Safety Reports
66%This webpage provides an overview of investigational new drug application (IND) safety reporting requirements for sponsors set forth in 21 CFR 312.32 and additional resources, including FDA guidances, related to these requirements.
Source: FDA
View evidenceInvestigational New Drug (IND) Application
66%Get to know the investigational new drug application (IND). This includes the types, laws and regulations, and emergency use of INDs.
Source: FDA
View evidenceFDA AP — SELEXIPAG (ORIG)
66%Application ANDA214055. Sponsor: RK PHARMA. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: SELEXIPAG.
Source: FDA
View evidenceFDA AP — BAXFENDY (ORIG)
66%Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
Source: FDA
View evidenceFDA AP — BAXFENDY (ORIG)
77%Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
Source: FDA
View evidenceFDA AP — BAXFENDY (ORIG)
77%Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
Source: FDA
View evidenceRegulatory Developments Enhance Competitive Landscape for Tyvaso in PAH Market
64%The FDA's acceptance of the supplemental application for Tyvaso signifies a potential shift in the competitive landscape for pulmonary arterial hypertension treatments. This could enhance United Therapeutics' market position and necessitate strategic adjustments from competitors. Regulatory context from FDA (FDA AP — BAXFENDY (ORIG)) supports the near-term read. Assessment grounded in 6 ranked evidence items (3 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Accepts Supplemental Application for UPTRAVI (Selexipag)
Regulatory Approval
- FDA Accepts Supplement Application for Tyvaso (Treprostinil)
Regulatory Approval
Insights
- Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH Market
Pulmonary Arterial Hypertension · Prostacyclin Analog
Companies
- United Therapeutics
3 signals